The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.

Stellbrink, H-J

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. [electronic resource] - HIV medicine 03 2020 - 3-16 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

1468-1293

10.1111/hiv.12833 doi


Adenine--adverse effects
Alanine
Anti-HIV Agents--adverse effects
CD4 Lymphocyte Count
Comorbidity
Drug Combinations
Emtricitabine
Equivalence Trials as Topic
HIV Infections--blood
Heterocyclic Compounds, 4 or More Rings--adverse effects
Humans
Piperazines
Pyridones
Risk Factors
Socioeconomic Factors
Tablets
Tenofovir--adverse effects